XBiotech Inc. Common Stock (XBIT)

About XBIT

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the f…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

87

Website

www.xbiotech.com/

Fundamentals

1-day range

$2.26$2.32

Market cap

$69.51M

P/E (trailing)

—

P/E (forward)

17.46

EPS (trailing)

$-1.32

Dividend yield

—

Beta

0.80

Avg. volume

34.6K

Ex-dividend date

July 15, 2021

Dividend pay date

July 23, 2021

XBiotech Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• XBIT

  XBiotech Inc. Common Stock

  $2.27

  ▼ 0.00%
  Market cap $69.51MP/E —
  $2.09$3.59
• FRMM

  Forum Markets Incorporated Common Stock

  $5.9

  ▲ 4.24%
  Market cap $70.30MP/E —
  $1.76$31
• IBIO

  iBio Inc. Common Stock

  $1.36

  ▼ 2.86%
  Market cap $70.54MP/E —
  $0.7708$3.82
• OSTX

  OS Therapies Incorporated Common Stock

  $1.64

  ▼ 2.38%
  Market cap $70.58MP/E —
  $1.15$2.54
• ACRV

  Acrivon Therapeutics Inc. Common Stock

  $2.06

  ▼ 4.19%
  Market cap $66.77MP/E —
  $1.27$3.56
• SPRO

  Spero Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $66.59MP/E 4.73
  $1.08$3.08
• ELTX

  Elicio Therapeutics Inc. Common Stock

  $2.86

  ▼ 4.67%
  Market cap $65.84MP/E —
  $2.66$16

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

1.92M

Total value held

$4.50M

Institutional holders

35